^
Association details:
| Biomarker: | HR positive |
|---|---|
| Cancer: | HER2 Negative Breast Cancer |
| Drug: | prexasertib (ACR-368) (Chk2 inhibitor, Chk1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Clinically relevant CHK1 inhibitors abrogate wild-type and Y537S mutant ERa expression and proliferation in luminal primary and metastatic breast cancer cells
Published date:
04/13/2022
Excerpt:
Data show that synergy between Tam and AZD or Prexa was detected only in MCF-7 (Fig. 10C and C’) and T47D-1 (Fig. 10D and D’) cells but not in BT-474 and MDA-MB-361 (Supplementary Fig. 5), thus supporting the concept that these inhibitors could be used in the combinatorial treatment of LumA rather than LumB BCs.
Secondary therapy:
tamoxifen
DOI:
10.1186/s13046-022-02360-y
